RestructuringNov 3, 2026, 06:11 AM
Karyopharm Therapeutics Files Chapter 11 Bankruptcy; Ayrmid to be Stalking Horse Bidder
AI Summary
Karyopharm Therapeutics Inc. and its subsidiary KPT Texas LLC have filed voluntary petitions for Chapter 11 bankruptcy. Ayrmid Ltd. will serve as the stalking horse bidder in a court-supervised sale process for a merger with a reorganized Karyopharm. The company has secured a commitment for $55 million in debtor-in-possession financing and expects operations to continue uninterrupted. A prepackaged Chapter 11 Plan of Reorganization has been filed, with a voting deadline of November 30, 2026. Existing equity interests will be cancelled as part of the restructuring.
Key Highlights
- Karyopharm Therapeutics Inc. and subsidiary KPT Texas LLC filed for Chapter 11 bankruptcy.
- Ayrmid Ltd. to serve as stalking horse bidder for a merger with reorganized Karyopharm.
- Company secured commitment for $55 million in debtor-in-possession (DIP) financing.
- Prepackaged Chapter 11 Plan of Reorganization filed, with voting deadline of November 30, 2026.
- Existing common stock, convertible preferred stock, and other equity interests to be cancelled.
- Company to continue operating as 'debtors-in-possession' with minimal disruption.
Price Impact
More from KPTI